ImPact Biotech presented updated positive data from its Phase 1 trial for Padeliporfin VTP in locally advanced pancreatic ductal adenocarcinoma (LA-PDAC) and Phase 3 ENLIGHTED trial in low-grade upper tract urothelial carcinoma (LG-UTUC) at ASCO 2026. In the Phase 1 LA-PDAC trial, 71% of patients became eligible for surgery after treatment, with a strong safety profile and no major complications. The Phase 3 ENLIGHTED trial showed a 70% complete response rate in evaluable LG-UTUC patients, with 85.7% maintaining response for at least 12 months. The company plans to submit a new drug application (NDA) for LG-UTUC in 2027 and is exploring commercialization opportunities while continuing clinical development.
The AI cryptocurrency sector reached a market cap of about $26.6 billion in May 2026, led by projects like Chainlink and NEAR Protocol. Ruvi AI (RUVI) stands out by integrating over 20 AI models into a decentralized platform that rewards contributors...
AIX Alpha has introduced a new AI-powered automated trading platform designed to help retail traders manage the increasing volatility in digital asset markets, particularly XRP. The system analyzes over 100,000 market signals daily and adjusts strate...
SpaceX is preparing for the largest IPO in history with its Starlink satellite network, targeting a valuation between $1.75 trillion and $2 trillion. This IPO will surpass previous tech giants' offerings by a huge margin and highlights the rapid grow...
Rumble Inc. is transitioning from video streaming to AI cloud services through its upcoming acquisition of Northern Data. This move positions the company to tap into major AI computing opportunities, with expected sales around $425 million driven by ...
Closed-end funds (CEFs) experienced tighter discounts and mixed net asset values (NAVs) through late May, with fixed-income CEFs underperforming equity funds due to distribution cuts and price pressures. Notably, CLO equity funds ECC and OXLC saw sha...
